These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 14965150)

  • 21. Consistency in the safety labeling of bioequivalent medications.
    Duke J; Friedlin J; Li X
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformity of package inserts information to regulatory requirements among selected branded and generic medicinal products circulating on the East African market.
    Sillo HB; Masota NE; Kisoma S; Rago L; Mgoyela V; Kaale EA
    PLoS One; 2018; 13(5):e0197490. PubMed ID: 29787579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual regulatory pharmaceutical labeling schemes; the role of the Federal Preemption Doctrine.
    Fern FH; Bartell L
    Health Matrix; 1987; 5(3):17-23. PubMed ID: 10285381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of various requirements of the quality assurance procedures for (18)F-FDG injection.
    Hung JC
    J Nucl Med; 2002 Nov; 43(11):1495-506. PubMed ID: 12411554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A; Wilson J
    Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
    [No Abstract]   [Full Text] [Related]  

  • 27. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

  • 28. A survey of top 200 drugs--inconsistent practice of drug strength expression for drugs containing salt forms.
    Prohotsky DL; Zhao F
    J Pharm Sci; 2012 Jan; 101(1):1-6. PubMed ID: 21905029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.
    ; ;
    Health Qual Life Outcomes; 2006 Oct; 4():79. PubMed ID: 17034633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
    Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Draft guidelines on compounding of nonsterile products in pharmacies. American Society of Hospital Pharmacists.
    Am J Hosp Pharm; 1993 Jul; 50(7):1452-61. PubMed ID: 8362883
    [No Abstract]   [Full Text] [Related]  

  • 32. "Doctor, are you trying to kill me?": ambivalence about the patient package insert for estrogen.
    Watkins ES
    Bull Hist Med; 2002; 76(1):84-104. PubMed ID: 11875245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The patient package insert and its legal implications.
    Cook D
    Leg Med Q; 1980; 4():258-70. PubMed ID: 10258797
    [No Abstract]   [Full Text] [Related]  

  • 35. Survey of safety and efficacy information in drug inserts for topical prescription medications.
    Zaghi D; Maibach HI
    Am J Clin Dermatol; 2007; 8(1):43-6. PubMed ID: 17298106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
    Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
    J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [How the managing role of the coordinator of nuclear medicine changes due to the new rules on: "Good preparation of the radiodrugs in nuclear medicine"].
    Massaro A; De Pieri P; Rubello D; Marcolongo A
    Minerva Med; 2009 Feb; 100(1):123-32. PubMed ID: 19088702
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug reactions: the role of the package insert.
    Barnett FJ
    J Leg Med (N Y); 1973; 1(1):19-23. PubMed ID: 4548069
    [No Abstract]   [Full Text] [Related]  

  • 39. National survey of quality assurance activities for pharmacy-prepared sterile products in hospitals.
    Crawford SY; Narducci WA; Augustine SC
    Am J Hosp Pharm; 1991 Nov; 48(11):2398-413. PubMed ID: 1746573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.